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Aims: The aim of this study was to investigate the initial cardiovascular prescription
patterns in patients after their first cardiovascular events, and to identify factors
associated with cardiovascular polypharmacy.
Methods: This was a cross-sectional study including patients aged ≥ 45 years with the
first record of coronary heart disease (CHD) or stroke between 2007 and 2016 using
The Health Improvement Network database. This study investigated the patterns of
cardiovascular drugs prescribed during the first 90 days after the first cardiovascular
events. Logistic regression was used to examine the association between patients'
baseline characteristics and cardiovascular polypharmacy (≥5 cardiovascular drugs).
Results: A total of 121,600 (59,843 CHD and 61,757 stroke) patients were included
in the study. The mean age was 69.5 ± 11.9 years. The proportion of patients who
were prescribed 0–1, 2–3, 4–5 drugs and ≥6 drugs were 11.0%, 29.8%, 38.6% and
20.5%, respectively. Factors associated with cardiovascular polypharmacy were sex
(female: OR 0.74, 95% CI 0.72–0.76 vs male), age (75–84 years old: OR 0.50,
0.47–0.53 vs 45–54 years old), smoking status (current smoking: OR 1.29, 1.15–1.24
vs never), body mass index (obesity: OR 1.38, 1.34–1.43 vs normal), deprivation status
(most deprived: OR 1.09, 1.04–1.14 vs least deprived) and Charlson comorbidity index
(index ≥5: OR 1.25, 1.16–1.35 vs index 0).
Conclusion: Multiple cardiovascular drugs treatment was common in patients with
CVD in the UK. High-risk factors of CVD were also associated with cardiovascular
polypharmacy. Further studies are warranted to assess the impact of cardiovascular
polypharmacy and its interaction on CVD recurrence and mortality.
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1 | INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of morbidity and
mortality worldwide, and its prevalence is increasing in line with the
ageing population. Coronary heart disease (CHD) and stroke are
the most common CVD conditions and are the top two causes of
death globally.1 According to the UK Heart and Circulatory Disease
Statistics 2019, adults aged 45 years and above accounted for the
majority of overall cardiovascular mortality (approximately 98.5%).2
Polypharmacy refers to the current use of multiple medications
by one individual.3 Cardiovascular conditions always appear to be the
main contributions to polypharmacy. A Scottish study on polypharmacy
found that the mean number of medications for patients with only
one condition of ischaemic heart disease is 3.7, and 8.0 for patients
with ischaemic heart disease and other co-conditions.4 Historically,
polypharmacy has been considered negatively, but it is now
increasingly recognised to be necessary and beneficial in patients
with some chronic disease (e.g. cardiovascular disease) if polypharmacy
is well managed. Currently, only a few studies have reported the
prescribing patterns of cardiovascular drugs.5–7 These studies only
investigated limited classes of cardiovascular drugs, rather than
providing a comprehensive overview of utilisation pattern. A UK
study indicated that cardiovascular risk factors influenced general
practitioners' decision to prescribe statins and antihypertensive drugs.8
However, it is unclear whether these factors are associated with the
prescribing of multiple medications. This study aimed to investigate the
initial prescription patterns of cardiovascular drugs in UK primary care,
and the association between potential risk factors and cardiovascular
polypharmacy in patients aged 45 years old and above following
their first records of coronary heart disease or stroke.
2 | METHODS
2.1 | Data source
The Health Improvement Network (THIN) database is a primary care
clinical database which includes anonymised data from general
practices across the UK. The database includes over 16 million
patients from over 744 general practices. In 2013, the active patients
in THIN represented approximately 6% of the UK population.9 THIN
includes information for each individual on demographics, diagnoses,
prescriptions, referrals, laboratory tests, immunisations and local area
deprivation (Townsend score).10 THIN data have been used previously
to study acute cardiovascular events.11
Ethics approval was obtained from the THIN Scientific Review
Committee (SRC), protocol reference: SRC 17THIN100.
2.2 | Study patients
The study included patients with the first general practitioner
(GP) record of CVD between January 2007 and December 2016. CVD
was defined based on Read Codes for CHD (myocardial infarction
(MI) and angina) and stroke (haemorrhagic stroke, ischaemic stroke
and transient ischaemic attacks [TIA]). Patients were divided into
groups (CHD and stroke groups) according to their first record of
CVD. Other inclusion criteria were patients aged 45 or above at
their first diagnosis of CVD and patients had been registered for
at least three years in THIN before their first diagnosis of CVD.
We excluded patients who died within the first 90 days following
the initial cardiovascular event, because their clinical data and
prescription information may not be recorded between the first
diagnosis and death.
2.3 | Initial treatment
In this study, initial pharmacotherapy with cardiovascular drugs in
each patient was defined according to the cardiovascular drugs
prescribed during the first 90-day window after the first recorded
CVD diagnosis. In the UK, repeat prescriptions are usually issued by
primary care physicians for chronic conditions. The prescription
interval is usually 28 or 56 days. Our study included CV drugs with
a prescription duration ≥ 28 days or with at least two prescriptions
during the 90-day exposure window. This was to make sure drugs
What is already known about this subject
• Concurrent use of different cardiovascular drugs is
common in patients with CVD.
• An appropriate number of CVD drugs (i.e. cardiovascular
polypharmacy) is necessary and beneficial in patients
with CVD.
• A few CVD drug utilisation studies from the literature
focused only on CVD drug classifications rather than the
number of CVD drugs.
What this study adds
• This study provides a comprehensive overview of CVD
drug patterns (including drug numbers and classifications)
in UK patients with new diagnoses of coronary heart
disease or stroke.
• Two-fifths of the cardiovascular patients had cardiovascu-
lar polypharmacy defined as concurrent use of five or more
CVD drugs.
• Male, younger age, currently smoking, higher deprivation
score, history of hypertension, hyperlipidaemia, and
multiple comorbidities were associated with the increased
use of cardiovascular polypharmacy.
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were prescribed for long-term use. Patients were also categorised
into groups according to the specific number or combination of
drugs prescribed. Cardiovascular drugs were identified from the
British National Formulary (BNF) Chapter two (cardiovascular
system). Compound medicines are separated into individual drug
constituents.
2.4 | Data extraction and missing data
Information on demographics, clinical characteristics and cardio-
vascular prescriptions were extracted from the THIN database.
Baseline characteristics included age, gender, smoking status, alcohol
consumption, body mass index (BMI), blood pressure (BP), total
cholesterol (TC), Townsend score, and comorbidities during the 1-year
window prior to the first cardiovascular event.
Missing data for each baseline characteristic were coded as a
separate category.
2.5 | Statistical analysis
All analyses were performed using SAS software version 9.4. Data
were presented as mean (standard deviation [SD]) for continuous
variables and as frequency (%) for categorical variables. Comparisons
were performed using student's t-test for continuous variables, and
the chi-squared test for categorical variables between the CHD and
stroke patients.
The study examined the percentage of CVD drugs prescribed
by the numbers of drugs (0, 1, 2, 3, 4, 5, 6, ≥7) issued during the
first 90 days following the diagnosis of CVD stratified by age
(10-year age groups up to ≥85 years), gender, smoking status
(never smoked, current smoker, ex-smoker), BMI (mean, normal,
overweight, obese and underweight), blood pressure (normal, stage
1, 2 and 3 hypertension and hypotension), total cholesterol
(optimal, intermediate and high), Charlson comorbidity index (excluding
myocardial infarction and cerebrovascular disease), history of
percutaneous transluminal coronary intervention (PCI), hypertension,
hyperlipidaemia, arrhythmia, heart failure (HF), dementia, diabetes,
chronic obstructive pulmonary disease (COPD), asthma, rheumatoid
arthritis (RA) or chronic kidney disease (CKD), and area deprivation
status (Townsend score 1–5).
The average number and the percentage of patients with
different numbers of CVD drugs in each calendar year were calculated.
The proportion of patients prescribed with the most commonly used
classes and combinations of CV drugs during the study period was
also investigated.
Odds ratios (ORs) and the corresponding 95% confidence
intervals (CIs) were evaluated by logistic regression model to examine
the association between baseline characteristics and CV polypharmacy
(prescribing of ≥5 CV drugs). All two-sided P-values less than 0.05 were
considered to be statistically significant.
3 | RESULTS
3.1 | Patient characteristics
From 2007 to 2016, 121,600 patients aged 45 years and above
were diagnosed with CVD. The study included 59,843 patients with
CHD (25,266 patients with angina and 34,577 patients with MI) and
61,757 patients with stroke. Patient characteristics at their first
CVD are presented in Table 1. The mean patient age at CV events
was 69.3 ± 11.7 years (67.0 ± 11.4 years for CHD patients and
71.7 ± 11.5 years for stroke patients). The proportion of male
patients with CVD was 55.5% (62.0% for CHD patients and 48.6% for
stroke patients).
3.2 | Usage of cardiovascular drugs
Figure 1 shows the percentage of patients receiving different
numbers of CV drugs after their first CVD events. Overall, 11.0% of
CVD patients had prescriptions for zero or one long-term used CV
drug, 29.8% were receiving two or three regular drugs, 38.6% were
receiving four or five drugs, and 20.5% were receiving six or more CV
drugs. The percentage of patients with CVD receiving cardiovascular
polypharmacy (≥5 CV drugs) was 40.6%. The average number of CV
drugs was 3.9 (SD: 1.9) in overall patients with CVD, 4.8 (SD: 1.8)
in patients with CHD, and 3.1 (SD: 1.7) in patients with stroke,
respectively. The majority of patients with CHD received five or more
drugs (61.1%). By contrast, patients with stroke received fewer CV
drugs; 62.5% were receiving two to four drugs.
Overall, in CVD patients, the most commonly prescribed CV
drugs were aspirin (59.9%), simvastatin (48.0%), clopidogrel (39.8%),
bisoprolol (34.5%), ramipril (30.5%) and atorvastatin (28.3%)
(Supporting Information Figure S1). In CHD patients, aspirin (79.0%),
bisoprolol (59.6%), clopidogrel (45.6%), ramipril (45.0%), simvastatin
(44.2%) and atorvastatin (38.6%) were frequently issued. In stroke
patients, simvastatin (51.8%), aspirin (41.4%), clopidogrel (34.3%),
amlodipine (18.4%), atorvastatin (18.4%) and ramipril (16.6%) were
commonly prescribed drugs.
Among patients with CHD, the most commonly used classes of
CV drugs were antiplatelet drugs (84.9%), lipid-regulating drugs
(85.3%), β-blockers (73.1%), angiotensin-converting enzyme inhibitors
(ACEIs)/angiotensin receptor blocker (ARBs) (67.7%) and antianginal
drugs (30.2%). Dual antiplatelet therapy was prescribed to 48.2% of
CHD patients. However, the proportions of dual antiplatelet therapy
and ACEIs/ARBs were 72.0% and 82.1% in patients with MI. In
patients with stroke or TIA, the most frequently prescribed CV drugs
were antiplatelet drugs (72.3%), lipid-regulating drugs (72.3%),
ACEIs/ARBs (43.8%), calcium-channel blockers (CCBs) (27.5%) and
diuretics (26.4%) (Figure 2). Prescribing for patients with MI and
angina are shown separately in Supporting Information Figure S2.
Details of specific combinations of the top five commonly
used classes of cardiovascular drugs in CHD and stroke patients are
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TABLE 1 Characteristics of the study population at their first CVD
Characteristics Total (n = 121,600) CHD (n = 59,843) Stroke (n = 61,757) P-value
Male (%) 67,073 (55.2) 36,894 (61.7) 30,179 (48.9) <0.01
Age, mean ± SD, years 69.5 ± 11.9 67.2 ± 11.5 71.8 ± 11.7 <0.01
Age groups, years (%)
45–54 15,370 (12.6) 9,540 (15.9) 5,830 (9.4) <0.01
55–64 27,427 (22.6) 16,235 (27.1) 11,192 (18.1)
65–74 34,262 (28.2) 17,119 (28.6) 17,143 (27.8)
75–84 31,134 (25.6) 12,517 (20.9) 18,617 (30.2)
85 and older 13,407 (11.0) 4,432 (7.4) 8,975 (14.5)
Smoking status (%)
Non-smoker 53,094 (43.7) 24,438 (40.8) 28,656 (46.4) <0.01
Current smoker 24,679 (20.3) 13,195 (22.1) 11,483 (18.6)
Ex-smoker 41,025 (33.7) 21,287 (35.6) 19,737 (32.0)
Missing 2,803 (2.3) 923 (1.5) 1,880 (3.1)
Alcohol consumption (%)
Non-drinker 18,767 (15.4) 9,143 (15.3) 9,624 (15.6) <0.01
Current drinker 66,108 (54.4) 34,390 (57.5) 31,718 (51.4)
Ex-drinker 4,280 (3.5) 2,136 (3.6) 2,144 (3.5)
Missing 32,445 (26.7) 14,174 (23.7) 18,271 (29.6)
BMI, mean ± SD 27.9 ± 5.3 28.2 ± 5.2 27.5 ± 5.3 <0.01
BMI groups (%)
Normal (18.5–24.9 kg/m2) 29,160 (24.0) 13,151 (22.0) 16,009 (25.9) <0.01
Overweight (25.0–29.9 kg/m2) 41,148 (33.8) 21,517 (36.0) 19,631 (31.8)
Obesity (≥ 30.0 kg/m2) 31,061 (25.5) 16,885 (28.2) 14,176 (23.0)
Underweight (< 18.5 kg/m2) 1,932 (1.6) 739 (1.2) 1,193 (1.9)
Missing 18,299 (15.1) 7,551 (12.6) 10,748 (17.4)
BP status (%)
Normal (BP < 140/90 mmHg) 40,689 (39.0) 21,539 (39.8) 19,150 (38.2) <0.01
Stage 1 hypertension (BP ≥ 140/90 mmHg) 31,458 (30.2) 15,944 (29.5) 15,514 (30.9)
Stage 2 hypertension (BP ≥ 160/100 mmHg) 10,371 (10.0) 4,900 (9.1) 5,471 (10.9)
Stage 3 hypertension (systolic BP ≥ 180 mmHg or
diastolic BP ≥ 110 mmHg)
4,312 (4.1) 1,713 (3.2) 2,599 (5.2)
Hypotension (BP < 90/60 mmHg) 157 (0.2) 101 (0.2) 56 (0.1)
Missing 17,276 (16.6) 9,878 (18.3) 7,398 (14.7)
TC status (%)
Optimal (<5.2 mmol/L) 48,685 (40.0) 23,624 (39.5) 25,061 (40.6) <0.01
Intermediate (5.3–6.2 mmol/L) 30,403 (25.0) 14,983 (25.0) 15,420 (25.0)
High (>6.2 mmol/L) 19,460 (16.0) 10,342 (17.3) 9,118 (14.8)
Missing 23,052 (19.0) 10,894 (18.2) 12,158 (19.7)
Townsend score (%)
1 (least deprived) 25,088 (20.6) 11,958 (20.0) 13,130 (21.3) <0.01
2 24,957 (20.5) 12,245 (20.5) 12,712 (20.6)
3 23,234 (19.1) 11,438 (19.1) 11,796 (19.1)
4 20,126 (16.6) 10,024 (16.8) 10,102 (16.4)
5 (most deprived) 14,240 (11.7) 7,310 (12.2) 6,930 (11.2)
Missing 13,955 (11.5) 6,868 (11.5) 7,087 (11.5)
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TABLE 1 (Continued)
Characteristics Total (n = 121,600) CHD (n = 59,843) Stroke (n = 61,757) P-value
Charlson comorbidity index (%)
0 59,272 (48.7) 29,492 (49.3) 29,780 (48.2) <0.01
1 29,763 (24.5) 14,740 (24.6) 15,023 (24.3)
2 13,481 (11.1) 6,263 (10.5) 7,218 (11.7)
3 10,953 (9.0) 5,383 (9.0) 5,570 (9.0)
4 4,785 (3.9) 2,372 (4.0) 2,413 (3.9)
≥5 3,346 (2.8) 1,593 (2.7) 1,753 (2.8)
History or PCI (%) 6,426 (6.2) 6,182 (11.4) 237 (0.5) <0.01
Comorbidity (%)
Hypertension 64,631 (53.2) 29,798 (49.8) 34,833 (56.4) <0.01
Hyperlipidaemia 19,242 (15.8) 10,164 (17.0) 9,078 (14.7) <0.01
Arrhythmia 14,847 (12.2) 5,430 (9.1) 9,417 (15.3) <0.01
Heart failure 6,992 (5.8) 4,379 (7.3) 2,613 (4.2) <0.01
Dementia 2,869 (2.4) 664 (1.1) 2,205 (3.6) <0.01
Diabetes 20,734 (17.1) 10,423 (17.4) 10,311 (16.7) <0.01
COPD 10,417 (8.6) 5,175 (8.7) 5,242 (8.5) 0.32
Asthma 16,705 (13.7) 8,469 (14.2) 8,236 (13.3) <0.01
RA 2,540 (2.1) 1,265 (2.1) 1,275 (2.1) 0.55
CKD 21,258 (17.5) 9,428 (15.8) 11,830 (19.2) <0.01
BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive
pulmonary disease; OR, odds ratio; PCI, percutaneous transluminal coronary intervention; RA, rheumatoid arthritis; TC, total cholesterol.
F IGURE 1 Percentage of patients receiving
different numbers of CV drugs
F IGURE 2 Percentage of patients receiving
particular classifications of CV drugs in separate
disease groups between 2007 and 2016
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presented in Table 2. Of the 59,843 patients with CHD, 4,896 (8.2%)
received none or one prescription of antiplatelet drugs, lipid-regulating
drugs, β-blockers, ACEIs/ARBs or antianginal drugs. The majority of
CHD patients were prescribed a combination of three (23.2%) or
four (44.1%) drug classes. The combined use of antiplatelet drugs,
lipid-regulating drugs, β-blockers and ACEIs/ARBs (34.3%) was most
frequently prescribed in CHD patients. In 61,757 patients with
stroke, 5,841 (9.5%) patients received none of antiplatelet drugs,
lipid-regulating drugs, ACEIs/ARBs, CCBs or diuretics. The percentage
of stroke patients received one, two and three of the five classes of
CV drugs was 13.0%, 29.0% and 27.4%, respectively. The combinations
of antiplatelet drugs and lipid-regulating drugs (18.6%), and the
TABLE 2 Combinations of the top five classes of CV drugs prescribed in patients with CHD and stroke
CHD (n = 59,843) Stroke (n = 61,757)
CV drugs Frequency % CV drugs Frequency %
None of the five class drugs 1,927 3.2 None of the five class drugs 5,841 9.5
One class 2,969 5.0 One class 8,043 13.0
APDs 844 1.4 APDs 3,515 5.7
LRDs 800 1.3 LRDs 2,560 4.2
BBs 563 0.9 ACEIs/ARBs 843 1.4
ACEIs/ARBs 466 0.8 CCBs 562 0.9
AADs 296 0.5 DRs 563 0.9
Two combination 6,444 10.8 Two combination 17,911 29.0
APDs + LRDs 2,100 3.5 APDs + LRDs 11,487 18.6
APDs + BBs 898 1.5 APDs + ACEIs/ARBs 1,053 1.7
APDs + ACEIs/ARBs 543 0.9 APDs + CCBs 692 1.1
APDs + AADs 372 0.6 APDs + DRs 744 1.2
LRDs + BBs 855 1.4 LRDs + ACEIs/ARBs 1,528 2.5
LRDs + ACEIs/ARBs 684 1.1 LRDs + CCBs 714 1.2
LRDs + AADs 257 0.4 LRDs + DRs 559 0.9
BBs + ACEIs/ARBs 423 0.7 ACEIs/ARBs + CCBs 446 0.7
BBs + AADs 164 0.3 ACEIs/ARBs + DRs 487 0.8
ACEIs/ARBs + AADs 148 0.3 CCBs + DRs 201 0.3
Three combination 13,894 23.2 Three combination 16,905 27.4
APDs + LRDs + BBs 5,262 8.8 APDs + LRDs + ACEIs/ARBs 7,667 12.4
APDs + LRDs + ACEIs/ARBs 3,728 6.2 APDs + LRDs + CCBs 3,397 5.5
APDs + LRDs + AADs 1,284 2.2 APDs + LRDs + DRs 2,076 3.4
APDs + BBs + ACEIs/ARBs 996 1.7 APDs + ACEIs/ARBs + CCBs 507 0.8
APDs + ACEIs/ARBs +AADs 413 0.7 APDs + ACEIs/ARBs + DRs 776 1.3
APDs + BBs + AADs 236 0.4 APDs + CCBs +DRs 285 0.5
LRDs + BBs + ACEIs/ARBs 1,180 2.0 LRDs + ACEIs/ARBs + CCBs 747 1.2
LRDs + BBs + AADs 368 0.6 LRDs + ACEIs/ARBs + DRs 942 1.5
LRDs + ACEIs/ARBs + AADs 288 0.5 LRDs + CCBs + DRs 275 0.5
BBs + ACEIs/ARBs + AADs 139 0.2 ACEIs/ARBs + CCBs + DRs 233 0.4
Four combination 26,382 44.1 Four combination 10,264 16.6
APDs + LRDs + BBs + ACEIs/ARBs 20,495 34.3 APDs + LRDs + ACEIs/ARBs + CCBs 3,912 6.3
APDs + LRDs + BBs + AADs 2,906 4.9 APDs + LRDs + ACEIs/ARBs + DRs 4,131 6.7
APDs + LRDs + ACEIs/ARBs + AADs 2,115 3.5 APDs + LRDs + CCBs + DRs 1,261 2.0
APDs + BBs + ACEIs/ARBs + AADs 400 0.7 APDs + ACEIs/ARBs + CCBs + DRs 351 0.6
LRDs + BBs + ACEIs/ARBs + AADs 466 0.8 LRDs + ACEIs/ARBs + CCBs + DRs 609 1.0
Five combination 8,227 13.8 Five combination 2,793 4.5
APDs + LRDs + BBs + ACEIs/ARBs + AADs 8,227 13.8 APDs + LRDs + ACEIs/ARBs + CCBs + DRs 2,793 4.5
AADs, antianginal drugs; ACEIs, angiotensin-converting enzyme inhibitors; APDs, antiplatelet drugs; ARBs, angiotensin receptor blockers; BBs, β-blockers;
CCBs, calcium channel blockers; CHD, coronary heart disease; CV, cardiovascular; DRs, diuretics; LRDs, lipid-regulating drugs.
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combination of antiplatelet drugs, lipid-regulating drugs and ACEIs/
ARBs (12.4%) were frequently prescribed to patients with stroke.
3.3 | Trends in initial therapy for secondary
prevention 2007–2016
Figure 3 shows the trends in the number of cardiovascular drugs issued
to CVD patients from 2007 to 2016. From 2010 the percentage of
patients receiving two drugs increased from 10.9% in 2010 to 15.8% in
2016. Conversely, the percentage of patients receiving six drugs (from
13.0% to 10.8%) and seven or more drugs (from 8.9% to 7.0%) showed
a declining trend from 2010 to 2016. When investigating the trends
in CHD and stroke separately, the CV drug usage remained stable
(Supporting Information Figures S3 and S4).
3.4 | Factors associated with cardiovascular
polypharmacy
Figure 4 shows the proportion of patients receiving different numbers
of cardiovascular drugs and the mean number of cardiovascular drugs
by the risk factor groups. Table 3 summarises the potential factors
predicting the probability of cardiovascular polypharmacy. Women
were less likely to be issued with five or more cardiovascular drugs
(OR: 0.74, 95% CI: 0.72–0.76). Patients receiving cardiovascular
polypharmacy decreased with increasing age (OR = 0.94, 0.81, 0.69
and 0.50 in patients aged 55–64, 65–74, 75–84 and 85 + years old,
respectively, vs patients aged 45–54 years old). Current smokers were
more likely to be receiving cardiovascular polypharmacy with an OR
of 1.19 (95% CI: 1.15–1.24). High BMI was shown to be associated
with cardiovascular polypharmacy as overweight patients (OR = 1.23,
95% CI: 1.19–1.27) and obese patients (OR = 1.38, 95% CI:
1.34–1.43) were significantly more likely to be prescribed five or more
cardiovascular drugs. Compared to patients with normal blood
pressure, the ORs were 1.06 (95% CI: 1.03–1.09), 1.08 (95% CI:
1.04–1.13) and 1.24 (95% CI: 1.17–1.32) for patients with stage
1, stage 2 and stage 3 hypertension, respectively. The area deprivation
status was associated with polypharmacy. Compared with patients
living in the least deprived area, the ORs of cardiovascular polypharmacy
increased with higher deprived areas (OR = 1.05 and 1.06 in patients
assigned a Townsend score of four and five, respectively). The
probability of receiving cardiovascular polypharmacy in patients with a
history of PCI was 5.26 times (95% CI: 4.96–5.58) compared to
patients with no history. High Charlson comorbidity index (CCI) was
also a predictive factor of cardiovascular polypharmacy with ORs of
1.22 (95% CI: 1.17–1.28), 1.31 (95% CI: 1.23–1.40) and 1.25 (95% CI:
1.16–1.35) in CCIs of three, four and five or more, respectively.
CVD patients with hypertension (OR: 2.03, 95% CI: 1.97–2.08),
hyperlipidaemia (OR: 1.16, 95% CI: 1.12–1.20), heart failure (OR: 2.57,
95% CI: 2.43–2.71), diabetes (OR: 1.25, 95% CI: 1.21–1.29), chronic
kidney disease (OR: 1.19, 95% CI: 1.16–1.24) and arrhythmia (OR: 1.05,
95% CI: 1.01–1.10) were more likely to be issued with five or more CV
drugs. Conversely, having a history of dementia (OR: 0.44, 95% CI:
0.40–0.49), COPD (OR: 0.92, 95% CI: 0.88–0.97) or asthma (OR: 0.90,
95% CI: 0.87–0.93) decreased the probability of CV polypharmacy.
4 | DISCUSSION
Although there are studies on drug utilisation for cardiovascular disease,
this is the first UK study to provide a comprehensive overview of initial
prescription patterns of cardiovascular drugs and investigate potential
factors associated with the probability of cardiovascular polypharmacy
in patients with new diagnoses of coronary heart disease or stroke. Our
results found that 40.6% of patients with CVD received cardiovascular
polypharmacy. The average number of cardiovascular drugs was 4.8 in
patients with CHD and 3.1 in patients with stroke. Male, younger age,
current smoking, high BMI, hypertension, hyperlipidaemia, higher depri-
vation score and multiple comorbidities were associated with an
increased likelihood of receiving cardiovascular polypharmacy.
Antiplatelet therapy, statins, ACEIs and beta-blockers are
recommended for all patients for the secondary prevention of
MI.12–15 We observed high rates of antiplatelet drugs (91.8%),
lipid-regulating drugs (89.8%), ACEIs/ARBs (82.1%) and β-blockers
(80.2%) in patients with MI. The proportion of patients prescribed
F IGURE 3 Trends in numbers and means of
the number of CV drugs prescribed to patients
with CVD from 2007 to 2016
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with dual antiplatelet (72.0%) therapy was relatively lower. In patients
with stroke, over 75% of stroke patients initially received at least one
of antiplatelet drugs and lipid-regulating drugs. ACEIs/ARBs (43.8%),
CCBs (27.5%) and diuretics (26.4%) were also frequently issued.
Guidelines state that blood pressure therapy is indicated for the
secondary prevention of stroke in patients who have a sustained
BP ≥ 140 mmHg systolic or ≥90 mmHg diastolic, and ACEIs/ARBs,
CCBs and diuretics are the first-line antihypertensive drugs.16 Our
results indicated that the usage of cardiovascular drugs in “real-world”
patients still suboptimally adhered to the guideline recommendations.
Between 2007 and 2016, the initial use of cardiovascular
drugs for the secondary prevention of CVD remained stable. This
trend is not surprising because ACEIs, aspirin, β-blockers and statins
were advocated to reduce mortality after acute MI in the NICE
guidelines published in 2001,17 which was consistent with the latest
version.15 Similarly, the first-line pharmacotherapy for stroke and TIA
recommended in the latest NICE guidelines was in accordance with
the guidelines published in 2008.12,18
We further investigated the association between the prescribing of
cardiovascular polypharmacy and potential risk factors at baseline. In our
analysis, women were less likely to have cardiovascular polypharmacy.
Several studies have reported underuse of cardiovascular drugs in
women after their first diagnosis of CVD.5–7,19 The AusHEART study19
reported that women were more likely to be underestimated by
physicians on the true risk of cardiovascular disease. A previous study
conducted in the UK has also suggested that women were less likely to
be systematically screened for cardiovascular disease than men.20
These might partially explain the gender difference in cardiovascular
drug prescribing.
In accordance with current evidence, the results of this
study found a lower rate of cardiovascular polypharmacy in older
patients.5,21,22 One potential reason could be that combination
F IGURE 4 Percentage of patients receiving different numbers of CV drugs by (A) sex, (B) age, (C) smoking status, (D) alcohol assumption,
(E) BMI status, (F) blood pressure status, (G) total cholesterol status, (H) Townsend score, (I) Charlson comorbidity index and (J) comorbidities
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therapy may be a less cost-effective regimen for older patients
because of a longer recovery period and shorter life expectancy.23 In
addition, for older patients, multiple factors like drug interactions and
potential adverse effects have to be considered, which may lead to an
underuse of drug therapies.24,25 Current smoking, high body mass
index, high blood pressure and hyperlipidaemia were shown to be
considerably and positively associated with initiating cardiovascular
polypharmacy, which might be attributable to awareness of the
increased risk of cardiovascular disease. CVD patients with a history
of PCI were more likely to be treated with five or more cardiovascular
drugs, which might be related to higher severity of disease condition
or additional medications prescribed as a result of intervention,
e.g. stenting.
Multi-comorbidities were also presented as a risk factor of
cardiovascular polypharmacy. CVD patients with a history of heart
failure, diabetes or chronic kidney disease often receive combination
therapy more frequently. In addition to the drugs for the secondary
prevention of CHD or stroke, guidelines recommend that those
patients with HF should be prescribed some other cardiovascular
drugs. For example, mineralocorticoid receptor antagonists are
indicated for patients who have HF with reduced ejection fraction
and continue to have symptoms of HF. Anticoagulant drugs combined
with antiplatelet drugs may be recommended for patients with
stroke and HF.26 Diabetes is a significant risk factor of cardiovascular
disease, so it would be expected that doctors may prescribe additional
cardiovascular drugs for those CVD patients with diabetes. Many
significant CVD risk factors including diabetes, hypertension and
dyslipidaemia are highly prevalent in patients with CKD.27 The
guidelines indicate that CKD patients should aim to control their
blood pressure below 140/90 mmHg and lower than 130/80 mmHg if
they also have diabetes.28 Therefore, CVD patients with CKD may be
prescribed more cardiovascular drugs. In contrast, patients with a
history of dementia were less likely to be prescribed more than five
cardiovascular drugs. The reason for the underuse of cardiovascular
drugs in dementia is uncertain. NICE guidelines suggest that some
commonly used drugs may cause cognitive impairment, which
might be a concern for doctors prescribing for patients who have
CVD and dementia.29 Our results showed that patients with asthma
also received cardiovascular polypharmacy less frequently, which
might be due to concerns about drug interactions as β-blockers have
been debated for many years to be contraindicated in asthma
patients.30 In addition, this study showed that high deprivation status
was associated with cardiovascular polypharmacy. This is probably
attributed to a poorer level of health associated with social deprivation.
This finding is similar to the result of a Scottish study.31
Polypharmacy has historically been considered negatively because
of the associated risk of adverse events and decreased adherence.32,33
It is now accepted that in many chronic conditions, polypharmacy is
F IGURE 4 (Continued)
MA ET AL. 1051
TABLE 3 Odds ratios for factors associated with cardiovascular polypharmacy
Variables Univariable OR (95% CI) Multivariable OR (95% CI)
Gender
Male 1 (reference) 1 (reference)
Female 0.72 (0.70–0.74) 0.74 (0.72–0.76)
Age group (years)
45–54 1 (reference) 1 (reference)
55–64 1.00 (0.96–1.04) 0.94 (0.90–0.98)
65–74 0.90(0.86–0.93) 0.81 (0.78–0.85)
75–84 0.77 (0.75–0.81) 0.69 (0.66–0.72)
85 and over 0.54 (0.52–0.57) 0.50 (0.47–0.53)
Smoking status
Non-smoker 1 (reference) 1 (reference)
Ex-smoker 1.17 (1.14–1.20) 1.09 (1.06–1.12)
Current smoker 1.22 (1.18–1.26) 1.19 (1.15–1.24)
Alcohol status
Non-drinker 1 (reference) 1 (reference)
Ex-drinker 0.98 (0.91–1.04) 0.88 (0.82–0.94)
Current drinker 1.06 (1.03–1.10) 0.98 (0.94–1.01)
BMI group
Normal 1 (reference) 1 (reference)
Overweight 1.39 (1.35–1.43) 1.23 (1.19–1.27)
Obese 1.75 (1.70–1.81) 1.38 (1.34–1.43)
Underweight 0.63 (0.57–0.70) 0.73 (0.66–0.82)
BP status
Normal 1 (reference) 1 (reference)
Stage 1 hypertension 1.08 (1.05–1.11) 1.06 (1.03–1.09)
Stage 2 hypertension 1.13 (1.09–1.18) 1.08 (1.04–1.13)
Stage 3 hypertension 1.32 (1.24–1.40) 1.24 (1.17–2.05)
TC status
Optimal 1 (reference) 1 (reference)
Intermediate 0.89 (0.86–0.91) 1.02 (0.99–1.05)
High 0.95 (0.92–0.98) 1.13 (1.09–1.17)
Townsend score
1 (least deprived) 1 (reference) 1 (reference)
2 1.03 (0.99–1.07) 1.03 (0.99–1.06)
3 1.05 (1.01–1.09) 1.03 (0.99–1.07)
4 1.08 (1.04–1.12) 1.05 (1.00–1.09)
5 (most deprived) 1.13 (1.09–1.18) 1.06 (1.04–1.14)
Charlson comorbidity index
0 1 (reference) 1 (reference)
1 1.01 (0.98–1.04) 1.01 (0.98–1.04)
2 0.99 (0.95–1.03) 1.05 (1.01–1.09)
3 1.28 (1.23–1.33) 1.22 (1.17–1.28)
4 1.41 (1.33–1.49) 1.31 (1.23–1.40)
≥5 1.34 (1.25–1.44) 1.25 (1.16–1.35)
History of PCI 4.73 (4.47–5.00) 5.26 (4.96–5.58)
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also therapeutically beneficial. Prescribing of appropriate multiple
cardiovascular drugs is necessary for these with high risk of recurrent
CV events. Our previous systematic review and meta-analysis
study assessed the effectiveness of evidence-based combination
pharmacotherapy (EBCP) and found that EBCP is associated with a
decreased risk of all-cause mortality and cardiovascular events in
patients with cardiovascular disease.34 However, our results found that
underuse of evidence-based pharmacotherapy still existed in patients
with cardiovascular disease (5.2% of individuals did not receive routine
CV medications and 5.8% only received one medication following their
initial CV events), and this finding was consistent with previous
studies.35,36 The high proportions of non-smokers and patients without
comorbidities in this group may partially explain the phenomenon of
underuse of CVD drugs. The result indicated that cardiovascular
risk factors may influence general practitioners' decision to prescribe
cardiovascular drugs.8 Evidence-based recommendations on personalised
medicine are still limited. Further studies are required to evaluate the
risk and benefit of cardiovascular polypharmacy when prescribing for
the prevention and treatment of cardiovascular disease.
4.1 | Strengths and limitations
Our study has several strengths. It used a large UK primary care data
source which is representative of the UK general population.
The analysis has provided comprehensive details about the patterns
of initial cardiovascular pharmacotherapy prescribing by primary
physicians in patients with coronary heart disease and stroke.
Our study also has limitations. Firstly, the dataset only provides
records of prescriptions; therefore, it was not possible to determine if
drugs were actually dispensed, taken or adequately used by patients.
However, as the current study aimed to describe the utilisation
patterns of CV drugs after the CV event, this will not affect our
results. Secondly, because the THIN database does not capture
data from hospital treatment and over-the-counter (OTC) drugs
(e.g., aspirin available OTC), the study was not able to address drug
usage outside the records from general practice which may lead to
an underestimation in the results. This may be important, especially
for patients under the age of 60 years who may be liable to pay
prescription charges in England.
5 | CONCLUSIONS
Multiple cardiovascular drug treatment was common in CVD
patients in the UK. High-risk factors of CVD were associated with
cardiovascular polypharmacy. Further studies are warranted to
assess the impact of cardiovascular polypharmacy and its interaction
on CVD recurrence and mortality.
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TABLE 3 (Continued)
Variables Univariable OR (95% CI) Multivariable OR (95% CI)
Comorbidity
Hypertension 1.41 (1.38–1.45) 2.03 (1.97–2.08)
Hyperlipidaemia 1.16 (1.12–1.20) 1.16 (1.12–1.20)
Arrhythmia 1.09 (1.05–1.12) 1.05 (1.01–1.10)
Heart failure 2.41 (2.29–2.53) 2.57 (2.43–2.71)
Dementia 0.35 (0.32–0.38) 0.44 (0.40–0.49)
Diabetes 1.55 (1.50–1.59) 1.25 (1.21–1.29)
COPD 0.94 (0.90–0.98) 0.92 (0.88–0.97)
Asthma 0.94 (0.90–0.97) 0.90 (0.87–0.93)
Chronic kidney disease 1.24 (1.21–1.28) 1.19 (1.16–1.24)
RA 0.98 (0.90–1.07) 1.08 (0.99–1.17)
BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive
pulmonary disease; OR, odds ratio; PCI, percutaneous transluminal coronary intervention; RA, rheumatoid arthritis; TC, total cholesterol.
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